Introduction {#s1}
============

The endoplasmic reticulum (ER) is the site for biogenesis of nearly all eukaryotic integral membrane proteins ([@bib61]). The defining feature of these proteins is the presence of one or more α-helical TMDs ([@bib76]). Successful biogenesis requires each of these TMDs to be moved from the aqueous phase of the cytosol into the hydrophobic core of the lipid bilayer ([@bib27]; [@bib82]). Although this insertion reaction can occur unassisted in vitro for some substrates ([@bib9]; [@bib10]), insertion in the crowded cellular environment typically requires factors that facilitate the reaction to minimize off-pathway outcomes such as aggregation, mislocalization, and degradation ([@bib4]; [@bib26]; [@bib31]; [@bib56]; [@bib81]).

The best understood insertion factor is the protein translocation channel formed by the heterotrimeric Sec61 complex ([@bib52]). Structural studies have demonstrated that the Sec61α subunit contains an hourglass pore across the membrane for polypeptide translocation ([@bib73]; [@bib77]). The wall of this pore contains a lateral gate that opens to provide hydrophobic domains in a substrate access to the lipid bilayer ([@bib25]; [@bib44]; [@bib79]). Thus, Sec61 is thought to facilitate TMD insertion by its distinctive architecture that connects the aqueous environment in the cytosol to the hydrophobic environment inside the membrane.

In addition to the Sec61 complex, the ER contains two other widely conserved insertases that both mediate the insertion of tail-anchored (TA) membrane proteins ([@bib27]). TA proteins contain a single TMD close to the C-terminus with a short unstructured domain translocated across the membrane ([@bib42]). This topology necessitates that the TMD is inserted post-translationally. The 'guided entry of TA proteins' (GET) pathway ([@bib12]; [@bib30]) culminates at a heterodimeric complex (made of the ER-resident membrane proteins Get1 and Get2) that inserts TA proteins delivered to it by the targeting factor Get3 ([@bib46]; [@bib81]). More recently, the ten-subunit 'ER membrane protein complex' (EMC) ([@bib15]; [@bib34]) was shown to insert TA proteins whose TMDs are insufficiently hydrophobic to effectively engage TRC40, the mammalian homolog of Get3 ([@bib26]).

In addition to TA proteins, EMC mediates co-translational insertion of TMDs close to the N-terminus in the N~exo~ topology (defined by a translocated N-terminus) ([@bib13]). Notably, the translocated domain is short and unstructured. When the N-terminus is extended and preceded by a signal peptide, insertion is no longer EMC-dependent and occurs instead via the Sec61α lateral gate ([@bib13]). Although the topology of N~exo~ TMDs is opposite to the TMDs of TA proteins, they are both terminal TMDs whose insertion is not accompanied by appreciable polypeptide translocation. The EMC-mediated insertion reactions of both types of terminal TMDs has been reconstituted with purified EMC in vitro ([@bib13]; [@bib26]), suggesting that they might use similar mechanisms ([@bib14]).

The ten subunits of mammalian EMC (termed EMC1 through EMC10) are poorly understood because they have very few clearly established domains or resemblance to proteins of known structure or biochemical activity ([@bib83]; [Figure 1A](#fig1){ref-type="fig"}). The one possible exception is the three-TMD protein EMC3, which is predicted to be topologically and evolutionarily related to Get1 and a subdomain of the prokaryotic insertase YidC ([@bib4]). It has been speculated that this potential structural similarity reflects a similarity in molecular function.

![EMC2•EMC8 and EMC2•EMC9 form complexes that can bind a TMD.\
(**A**) Diagram of predicted EMC mass distribution and subunits. (**B**) Size exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) analysis of recombinant EMC2•EMC9 reveals a stable complex in a 1:1 ratio at the expected molecular weight of 59 kDa (orange). Recombinantly expressed EMC8 analyzed independently has a Mw of 23 kDa consistent with a monomeric state (teal). Addition of EMC8 to a pre-formed EMC2•EMC9 complex does not result in the formation of a ternary complex (grey). (**C**) ^35^S-methionine-labeled TA^SQS^ containing the benzoyl-phenylalanine (Bpa) photo-crosslinker within the TMD was produced as a defined complex with CaM using the PURE in vitro translation system. Bpa is incorporated into the TMD by amber suppression. Addition of EGTA releases CaM. The released TA^SQS^ will either aggregate or be protected from aggregation by a TMD-binding protein. The outcome can be monitored by UV-mediated crosslinking via Bpa to nearby proteins. The position of crosslinks between TA^SQS^ and various partners are indicated. No UV-mediated crosslinks are seen when TA^SQS^ does not contain an amber codon (lanes 1 and 2).](elife-57887-fig1){#fig1}

The membrane subunit EMC3 is in complex with six other integral membrane EMC subunits (1, 4, 5, 6, 7, and 10) that together contain 12 predicted TMDs ([@bib14]; [@bib15]; [@bib83]). The seven membrane subunits of EMC associate with the cytosolic subunits EMC2, EMC8, and EMC9. EMC8 and EMC9 are \~44% identical in mammals, and not all species contain both genes ([@bib83]). Whether they are both part of a single 10-protein complex or substitute for each other in a 9-protein complex is not known. No free population of individual subunits has been detected ([@bib13]; [@bib26]; [@bib74]), and disruption of most EMC subunits causes loss of EMC integrity and function ([@bib74]). Thus, EMC is thought to function as a stable complex to mediate TMD insertion. Notably, this reaction appears to be energy independent in reconstitution assays in vitro ([@bib26]), consistent with the absence of any nucleotide-binding domain in any of its subunits ([@bib83]).

EMC has also been suggested to act as a co-translational chaperone that captures individual or bundles of TMDs as they exit laterally from the Sec61 complex ([@bib65]). This postulated function has been inferred from analysis of EMC-mediated co-translational proximity biotinylation of ribosomes translating membrane proteins. How EMC might act as a chaperone, and the relationship of this function to its insertase activity, is not known. Consistent with either function, many membrane proteins are partially or strongly impacted in their biogenesis by the loss of EMC in numerous organisms including yeast, worms, flies, and mammals ([@bib7]; [@bib13]; [@bib26]; [@bib43]; [@bib45]; [@bib53]; [@bib57]; [@bib65]; [@bib68]; [@bib70]; [@bib74]). Thus, EMC is a highly abundant component of the ER needed for cellular and organism homeostasis.

Understanding the function(s) of EMC requires knowledge of its structure. By analogy to the Sec61 complex, EMC's insertase function might involve a path from the cytosol into the membrane. To investigate this idea, we used a combination of biochemical, biophysical, and structural approaches to determine the architecture of EMC. Our findings suggest that the cytosolic subunits initially engage a TMD in a weakly hydrophobic vestibule that is contiguous with an intramembrane groove open to the lipid bilayer. This work provides a mechanistic framework for how the highly abundant and conserved EMC functions as a TMD insertase, explains why EMC acts preferentially on terminal TMDs, and suggests that EMC is unlikely to chaperone TMDs released at the Sec61α lateral gate.

Results {#s2}
=======

Cytosolic EMC subunits can engage a substrate TMD {#s2-1}
-------------------------------------------------

Purified native EMC reconstituted in proteoliposomes is sufficient to catalyze the insertion of a TA protein substrate containing the TMD from squalene synthase (SQS) ([@bib26]). Because insertion of the SQS TMD into protein-free liposomes is comparatively inefficient, EMC is likely to transiently engage its substrate analogous to how other insertases interact with TMD substrates during insertion ([@bib37]; [@bib81]; [@bib88]). Reasoning that the first point of engagement by EMC might involve EMC's cytosolic subunits, we began by defining the interactions between EMC2, EMC8, and EMC9, then analyzing these proteins for their capacity to engage substrate.

Purified recombinant EMC2 formed a stable complex with either EMC8 or EMC9. Size exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) showed that each individual protein is monomeric and the EMC2•EMC8 and EMC2•EMC9 complexes are heterodimers ([Figure 1B](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The EMC2•EMC9 heterodimer did not form a ternary complex with excess EMC8, and the EMC2•EMC8 heterodimer did not form a ternary complex with excess EMC9. Thus, the cytosolic domain of EMC is likely to be composed of EMC2 in complex with either EMC8 or EMC9, but not both. The presence of only one of either EMC8 or EMC9 in native EMC may explain why some species have only one of these two genes ([@bib83]).

To analyze substrate interaction, a ^35^S-labeled TA protein containing the TMD of SQS (TA^SQS^) was produced in vitro using a fully purified translation system derived from *E. coli *components ([@bib64]). The photocrosslinking amino acid 4-Benzoylphenylalanine (Bpa) was incorporated within the TMD by amber suppression and TA^SQS^ was kept soluble by including an excess of the chaperone-like protein calmodulin (CaM) ([@bib26]; [@bib62]). UV irradiation of this complex produced a TA^SQS^-CaM crosslinked product which was diminished if CaM was inactivated by chelation of Ca^2+^ with EGTA ([Figure 1C](#fig1){ref-type="fig"}, lanes 4, 5). Without a chaperone, SQS formed self-crosslinks due to its aggregation as documented previously ([@bib26]). Release of SQS from CaM in the presence of EMC2•EMC8 or EMC2•EMC9 showed crosslinks to EMC2, EMC8, and EMC9 concomitant with a reduction of the TA^SQS^ aggregate crosslink ([Figure 1C](#fig1){ref-type="fig"}, lanes 7,8). This effect of the EMC2•EMC8 and EMC2•EMC9 complexes is similar, but less complete, than the effect seen with the TMD chaperone SGTA ([@bib60]; [Figure 1C](#fig1){ref-type="fig"}, lane 6). Analysis of individual subunits at various concentrations showed that EMC2 inhibited aggregation with a similar potency as the heterodimeric complexes, whereas EMC8 showed somewhat lower potency and EMC9 was largely inert ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

These observations indicate that the cytosolic domain of EMC contains a TMD-binding heterodimer of the EMC2•EMC8 subcomplex or the homologous EMC2•EMC9 subcomplex. Interchangeability of EMC8 and EMC9 explains why knockdown of EMC8 is accompanied by increased EMC9 ([@bib74]), and why individual knockdowns do not impact EMC substrates but the double-knockdown does ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Whether there are functional differences between EMC8- versus EMC9-containing EMC for certain substrates remains to be determined.

Crystal structure of the EMC2•EMC9 complex {#s2-2}
------------------------------------------

Recombinant cytosolic subunits and subcomplexes were screened for crystal formation, resulting in well-diffracting crystals of a nearly full length complex containing EMC2 and EMC9. This complex, lacking only short regions at the termini, was verified to be functional for substrate interaction by the photo-crosslinking assay (data not shown). The EMC2•EMC9 structure was solved with experimental phases from a single-wavelength anomalous diffraction (SAD) experiment using endogenous sulphur atoms for anomalous signal ([@bib80]). An initial model was built de novo and subsequently used as a molecular replacement search model for a native crystal diffracting X-rays to 2.2 Å ([Table 1](#table1){ref-type="table"}).

###### X-ray data collection and refinement statistics.

                             EMC2•EMC9                 EMC2•EMC9
  -------------------------- ------------------------- ------------------------
  Data collection                                      
  X-ray source               Diamond I23               Diamond I03
  X-ray wavelength (Å)       2.7552                    0.9763
  Space group                *P*2~1~2~1~2~1~           *P*2~1~2~1~2~1~
  Unit cell parameters                                 
  a, b, c (Å)                53.2 82.8 124.0           52.6 84.9 122.6
  α, β, γ (°)                90.0 90.0 90.0            90.0 90.0 90.0
  Resolution range (Å)       49.6--2.65 (2.78--2.65)   49.7--2.20 (2.27--2.2)
  No. of reflections                                   
  Total                      668148 (73113)            1486886 (128644)
  Unique                     16468 (2109)              28668 (2433)
  Completeness (%)           99.7 (98.9)               100.0 (100.0)
  Multiplicity               40.6 (34.7)               51.9 (52.9)
  I/σ(I)                     36.8 (1.8)                17.6 (1.9)
  R~meas~ (%)                6.4 (214.6)               17.2 (465.7)
  R~merge~ (%)               6.3 (211.5)               17.0 (461.3)
  R~pim~ (%)                 1.0 (35.3)                2.4 (63.7)
  CC~1/2~ (%)                100.0 (81.7)              100.0 (92.6)
  Refinement                                           
  R~work~/R~free~ (%)        \-                        20.3/25.0
  RMS deviations                                       
  Bond length (Å)            \-                        0.007
  Bond angle (°)             \-                        0.848
  No. of atoms                                         
  Protein                    \-                        3454
  Ligands                    \-                        72
  Water                      \-                        80
  Average B-factors (Å^2^)                             
  Total                      \-                        70.6
  Protein                    \-                        71.7
  Ligands and waters         \-                        65.4
  Ramachandran (%)                                     
  Favored                    \-                        96.4
  Outliers                   \-                        0.0
  PDB Code:                  \-                        6Y4L

^\*^(\*) Values in brackets are for the highest resolution bin.

EMC2 is largely alpha-helical and contains a curved tetratricopeptide repeat (TPR) motif buttressed on one side by EMC9 ([Figure 2A](#fig2){ref-type="fig"}). The core of EMC9 consists of a small β-barrel flanked by alpha-helices. The \~1100 Å^2^ EMC2-EMC9 interface contains a network of hydrogen bonds and salt bridges ([@bib39]), explaining its high stability in vitro and the absence of any appreciable free population of either protein in cells. EMC2 and EMC9 both contribute to the formation of a large, relatively shallow and moderately hydrophobic cavity that we term the cytosolic vestibule ([Figure 2B](#fig2){ref-type="fig"}).

![Structure of the EMC2•EMC9 complex.\
(**A**) Crystal structure of the EMC2•EMC9 heterodimer (PDB: 6Y4L). The heterodimer consists of EMC2 (residues 11--274), depicted in blue, and EMC9 (residues 1--200), depicted in orange. The TPR-repeat motif of EMC2 is indicated. (**B**) Physicochemical properties of a vestibule in the EMC2•EMC9 complex. Surface rendering of crystal structures coloured according to chemical properties ([@bib28]).](elife-57887-fig2){#fig2}

A reference-free model of EMC8 predicted by Rosetta ([@bib54]) possessed the same core fold as the EMC9 structure with a RMSD of 2.3 Å. When EMC9 was used as a reference ([@bib66]), the alpha-carbon backbone of the EMC8 model was indistinguishable from EMC9 with an RMSD of 0.6 Å ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This observation is consistent with their high homology (\~44% identity) and comparable affinity for EMC2 ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). We therefore conclude that the EMC2•EMC8 structure is likely to be very similar to EMC2•EMC9 explaining why the absence of either one has no obvious phenotype in cells.

Functional analysis of the vestibule in the EMC2•EMC9 complex {#s2-3}
-------------------------------------------------------------

Based on the ability of a substrate TMD to photo-crosslink with both EMC2 and EMC9, we posited that a TMD might bind to the vestibule in the EMC2•EMC9 complex. The moderate hydrophobicity of this region in both the EMC2•EMC9 structure and EMC2•EMC8 model is consistent with the moderate potency of these complexes in preventing substrate aggregation in aqueous solution. To test whether substrate binds in this cavity, we prepared the EMC2•EMC9 complex containing the photo-crosslinker Bpa at various sites and tested UV-mediated crosslinking to the TMD of SQS ([Figure 3A and B](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In this experiment, we used a substrate that contains only the TMD and a few flanking residues (termed TMD^SQS^), allowing us to be sure that the crosslinks are to the TMD. These findings verify that the cavity can engage substrate TMDs and map an approximate binding site that spans both EMC2 and EMC9.

![Functional analysis of the EMC2•EMC9 cytosolic vestibule.\
(**A**) ^35^S-methionine-labeled TMD of SQS was mixed with recombinant purified EMC2•EMC9 complex as in [Figure 1](#fig1){ref-type="fig"} and analyzed directly or after UV irradiation as indicated. The photocrosslinking amino acid benzoyl-phenylalanine (Bpa) was incorporated into either the SQS substrate, EMC9 (at codon 167), or EMC2 (at codon 193) as indicated. Both R167 in EMC9 and Q193 in EMC2 line the vestibule. (**B**) Bpa was incorporated at different positions within the vestibule of the EMC2•EMC9 complex and crosslinking efficiency to SQS was determined as in panel A. Locations of the Bpa are annotated as spheres on the EMC2•EMC9 heterodimer. The sphere colors correspond to the intensity of the resulting crosslink. Position 191 (obscured behind L190 in this view) showed no crosslinking to substrate, consistent with its rearward facing location. (**C**) Shown on the left is a diagram of the dual color reporter for insertion of the TMD of SQS. Expression of this reporter results in a free GFP protein and an RFP-tagged SQS protein due to ribosomal skipping at the a viral 2A sequence. The left graph shows flow cytometry analysis of the SQS reporter in WT cells (grey), EMC2 knockout (KO) cells (shaded pink), KO cells complemented with WT EMC2 (blue line), and KO cells complemented with the HLY\* EMC2 mutant (red line). The data are represented as histograms of the RFP to GFP ratio. The right graph shows a comparison of the SQS reporter in KO cells complemented with either WT EMC2 or the IMA\* EMC2 mutant. The mutated amino acids, whose positions are shown in panel B, are: H189E, L190E, Y191K, I61K, M95K, and A122E.](elife-57887-fig3){#fig3}

To test the functional relevance of the vestibule, we perturbed its physicochemical properties at regions that form relatively strong versus relatively weak crosslinks with substrate and analyzed EMC function in cells. Due to the redundancy of EMC2•EMC8 and EMC2•EMC9 heterodimers, we focused our mutational analysis on EMC2. Various residues in EMC2 were mutated individually or in combination to charged amino acids and tested for insertion of a SQS-based reporter in cultured cells ([Figure 3C](#fig3){ref-type="fig"}; [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). In this flow cytometry assay, failed insertion of RFP-tagged SQS results in a lower RFP signal due to its degradation relative to an internal GFP control ([@bib26]). As reported previously for other EMC subunit knockouts ([@bib26]; [@bib74]), the RFP:GFP ratio was very low in ΔEMC2 U2OS cells, but restored to normal levels when wild type EMC2 was re-expressed ([Figure 3C](#fig3){ref-type="fig"}, left graph).

A combination of H189E, L190E, and Y191K (termed HLY\*) in the region of highest substrate crosslinking showed reduced insertion by this assay ([Figure 3C](#fig3){ref-type="fig"}, left graph). Individual mutations of these residues had little or no effects ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). Mutation of adjacent residues that were already hydrophilic (Q193E and Q194K) showed no effect ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}), suggesting that a substantial change in hydrophobicity or possibly a change in local conformation was needed to appreciably impact substrate insertion. The IMA\* mutation, which causes a similarly large loss of hydrophobicity to the region of EMC2's vestibule where substrate crosslinking is weak, showed almost no impairment in substrate insertion ([Figure 3C](#fig3){ref-type="fig"}, right graph). Importantly, we verified that the HLY\* mutation did not impair EMC2 incorporation into the native EMC ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}), unlike the A129K mutation whose strong phenotype ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}) could be ascribed to poor assembly ([Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}). Thus, there is concordance between EMC2 regions of the vestibule that interact with a TMD substrate in vitro and mutations that perturb substrate insertion in cells.

Position of the EMC2•EMC9 subcomplex within native EMC {#s2-4}
------------------------------------------------------

Once a TMD substrate binds to the cytosolic subunits of EMC, subsequent insertion requires access to the lipid bilayer. To understand how the substrate-binding cavity within the cytosolic subunits is oriented relative to the membrane, we sought to place our EMC2•EMC9 structure within the architecture of native EMC. Affinity-purified EMC representing a mixture of EMC8- and EMC9-containing complexes ([@bib26]) were analyzed by single-particle cryo-EM. The map clearly shows density for the lumenal, transmembrane, and cytoplasmic regions of EMC ([Figure 4A](#fig4){ref-type="fig"}). Due to preferential orientation, the resulting density map was limited to modest resolution of (6.5 Å) throughout the structure ([Table 2](#table2){ref-type="table"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

![The position of EMC2•EMC9 within native EMC.\
(**A**) Cryo-EM map of the EMC at 6.4 Å resolution reveals the architecture of the complex. The map is shown at two contour levels: a stringent contour that illustrates secondary structure features (0.21) superimposed with a liberal contour that shows the detergent micelle (0.15). (**B**) Refinement of the EMC2•EMC9 crystal structure (blue and orange) into the cytosolic density (grey) using Flex-EM, Coot and PHENIX. (**C**) Surface rendering of the EMC2•EMC9 crystal structure coloured by residue conservation ([@bib5]) from highly conserved (purple) to weakly conserved (green). The top rim of EMC2's TPR is highly conserved. This surface faces the membrane and regions of it interact with other EMC-subunits. The substrate binding vestibule also exhibits high conservation in comparison to the remaining solvent exposed surface of the EMC2•EMC9 heterodimer.](elife-57887-fig4){#fig4}

###### Cryo-EM data collection and processing.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          Dataset 1                Dataset 2                Dataset 3                Dataset 4      Dataset 5
  ----------------------------------------------------------------------- ------------------------ ------------------------ ------------------------ -------------- --------------
  Microscope                                                              Titan Krios (m06 eBIC)   Titan Krios (m06 eBIC)   Titan Krios (m06 eBIC)   Titan Krios\   Titan Krios\
                                                                                                                                                     (MRC-LMB)      (MRC-LMB)

  Pixel Size                                                              1.380                    1.380                    1.380                    1.179          1.390

  Voltage                                                                 300                      300                      300                      300            300

  Spherical Aberation                                                     2.7                      2.7                      2.7                      2.7            2.7

  Total exposure (e^-^/Å^2^)                                              39.60                    42.50                    37.77                    39.36          44.36

  Exposure Length (s)                                                     5.0                      11.02                    14                       11             11

  Frames                                                                  25                       44                       40                       44             40

  Defocus Range (µm)                                                      −0.5 to −1.5             −0.5 to −1.5             −0.5 to −1.5             −0.5 to −1.5   −0.5 to −1.5

  Micrographs                                                             2776                     2484                     1206                     4228           932

  Microscope tilt (degrees)                                               0                        0                        30                       20             20

  Volta Phase Plate                                                       ✓                        ✓                        ✓                        ✓              ✓

  Pre-merge processing                                                    Dataset 1                Dataset 2                Dataset 3                Dataset 4      Dataset 5

  Motion Correction and CTF estimation (micrographs)                      2776                     2484                     1206                     4228           932

  Blob-based autopicking (particles)                                      1,298,488                541,233                  319,989                  1,145,157      223,613

  2x iterations of 2D classification (particles)                          63,180                   63,315                   51,371                   305,685        28,662

  Template based autopicking (particles)                                  467,323                  687,645                  826,006                  N/A            273,852

  2D classification (particles)                                           11,862                   71,977                   63,881                   113,852        66,799

  Ab Initio 3D classification (particles)                                 103,105                  71,977                   46,349                   113,852        50,232

  Post-merge processing                                                   Combined Datasets                                                                         

  2x Iterations *ab initio* 3D classification (particles)                 405,515                                                                                   

  Non-uniform Refinement (particles)                                      167,294                                                                                   

  Per-particle CTF refinement                                             6.71 Å map                                                                                

  Non-uniform refinement with local resolution estimation and filtering   6.4 Å map                                                                                 

  EMDB Deposition code                                                    EMD-11058                                                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Although atomic models could not be built de novo from the EM map, this resolution was sufficient to dock the EMC2•EMC9 crystal structure. The only region of EMC2•EMC9 that did not precisely align with the EM-density was the first three alpha-helices of EMC2 comprising residues 11--66 ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Low frequency normal mode analysis ([@bib67]) predicted that these three helices undergo structural movement that would be compatible with the EM-density. Therefore, the EMC2•EMC9 structure was refined against the EM-density using Flex-EM, ([@bib71]), *Coot* ([@bib18]), and PHENIX real-space refinement ([@bib2]), resulting in a slightly rotated position that fits into the EM-density ([Figure 4B](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

The plane of the membrane was evident from the detergent micelle surrounding the TMD region of EMC ([Figure 4A](#fig4){ref-type="fig"}). Relative to the membrane, the EMC2•EMC9 complex is oriented such that the TPR-repeats of EMC2 are proximal to the membrane but angled at \~30°. In this configuration, the substrate binding cavity of EMC2•EMC9 has access to both the bulk cytosol and the membrane domain of EMC ([Figure 4B](#fig4){ref-type="fig"}). The surface of EMC2 that faces the membrane domain is also highly conserved, consistent with this region making contacts with the membrane-embedded subunits of EMC ([Figure 4C](#fig4){ref-type="fig"}). Thus, the cytosolic subunits of EMC are arranged so the cavity capable of binding substrate forms a vestibule that links the cytosol to the integral membrane subunits that would act next to mediate TMD insertion.

The region of the vestibule that binds substrates as determined in crosslinking assays is occupied in the cryo-EM map by density that is contributed from another EMC subunit (possibly EMC6, as discussed below). Intramolecular placeholders that temporarily shield the substrate-binding pockets are also observed in the membrane protein targeting factors SRP and Get3 ([@bib47]; [@bib78]). In both of these other examples, the placeholders are less hydrophobic than substrate TMDs, allowing their displacement by bona fide substrates but presumably not other proteins. EMC may therefore operate similarly. Thus the putative placeholder density might provide an approximation of what a substrate-bound intermediate of EMC looks like. From this position, an inserting substrate would next have to engage the region of EMC embedded in the membrane.

Architecture of the membrane-embedded and lumenal regions of EMC {#s2-5}
----------------------------------------------------------------

A cross section through the detergent micelle of the EMC map in the plane of the membrane showed the arrangement of thirteen putative TMD helices ([Figure 5A](#fig5){ref-type="fig"}). To assign the intramembrane densities to individual EMC subunits, we first generated starting models for those that contain two or more TMDs. Using trRosetta ([@bib87]), which employs co-evolutionary data, deep learning, and inter-residue contacts for energy minimization of structural models, we produced models for EMC3, EMC4, EMC5, and EMC6 ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Even though trRosetta does not consider biological membranes or topology, the predicted TMDs of EMC3 and EMC5 pack together as helices whose lengths match the thickness of a lipid bilayer. Strikingly, trRosetta accurately predicted the structures of EMC2, EMC9, and Sec61α, providing confidence in its capacity to produce starting models for both soluble and integral membrane domains.

![A composite model of EMC's membrane and lumenal domains.\
(**A**) Cross section through the TMD region of the cryo-EM map of EMC (light grey) identifies 13 helix-like densities (dark blue) that define an intramembrane groove (red star) open to the lipid bilayer. Density corresponding to the annular detergent micelle is indicated. (**B**) Ab initio trRosetta models fitted into cryo-EM density for the EMC membrane domain are shown for EMC1 (wheat), EMC3 (orange), EMC4 (light pink), EMC5 (red), EMC6 (teal), and EMC7 (green). The horizontal density at the membrane-lumen interface termed the 'crossbar' is assigned to an amphipathic helix in EMC1. (**C**) EMC3-3xFLAG constructs containing amber codons (amb.) at the indicated positions were expressed together with an amber suppressor tRNA and cognate aminoacyl-tRNA synthetase that accepts the UV-activated crosslinking amino acid 3\'-azibutyl-N-carbamoyl-lysine (AbK). Cells were left untreated or irradiated with UV and analyzed by immunoblotting for EMC3-3xFLAG. A prominent UV-dependent crosslink is seen from position 23 and to a lesser extent, position 26. Native FLAG immunoprecipitation (IP) recovers EMC1 (indicating that EMC3-3xFLAG is incorporated into EMC), which shifts with UV. Denaturing EMC1 IP confirms the crosslinked product contains both EMC1 and EMC3. (**D**) TMD helices positioned based on docking of ab initio models overlayed with AbK-mediated crosslinks (see [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). The positions where AbK was incorporated are shown as spheres, with magenta lines showing the closest point of the target protein in the model. (**E**) Composite model of the EMC lumenal domain generated by ab initio modelling in trRosetta and real-space refinement in PHENIX. Cryo-EM density has been colored according to subunit identity and the composite lumenal domain model accounts for almost all the lumenal EM density. (**F**) Cross-section through EMC at the plane of the membrane-lumen interface illustrating that a pore is not evident across the membrane. All EM data visualized in UCSF ChimeraX with EM maps contoured at 0.15 (panel A) and 0.21 (panels B, E, and F) with hide dust setting of 10. Panel D was generated in PyMOL.](elife-57887-fig5){#fig5}

Although we had previously predicted two TMDs for EMC6 based on hydrophobicity profiles ([@bib40]), trRosetta generated a three-helix bundle ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) that matched the consensus of other topology prediction algorithms ([@bib72]). More surprisingly, EMC4 also is predicted by trRosetta to have three TMD-like helices, not two as previously thought based on topology algorithms. Protease-protection assays resolved this discrepancy in favor of the trRosetta model because we found that the N-terminus of EMC4 faces the cytosol and the C-terminus is in the ER lumen ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

The trRosetta models for EMC3, EMC6, and EMC5 could be docked at distinctive positions into the EM map based on their helix lengths and relative tilts ([Figure 5B](#fig5){ref-type="fig"}). The main remaining region that could accommodate a three-helix bundle was therefore assigned to EMC4. This left two TMD-like densities and three single-spanning EMC subunits (EMC1, EMC7, and EMC10). Because EMC10 can be depleted with no functional consequences ([@bib74]), we suspected this subunit was probably peripheral and least likely to be visualized in the map. We therefore assigned the two remaining TMD-like densities to EMC1 and EMC7, distinguishing between them using a site-specific photo-crosslinking approach.

The photo-crosslinking amino acid 3\'-azibutyl-N-carbamoyl-lysine (AbK) was introduced by amber suppression ([@bib3]) into specific sites of individual FLAG-tagged EMC subunits. The cells were then UV-irradiated to induce crosslinks with nearby proteins (with a backbone-to-backbone distance of \~10--15 Å) and the samples were analyzed by immunoprecipitation and immunoblotting. Three and four sequential positions were tested within a TMD to sample different radial directions ([@bib48]). Introduction of AbK at position I23^AbK^ in the first TMD of EMC3 showed a strong high-molecular weight crosslink consistent with the size of EMC1. EMC1 immunoblotting of natively purified EMC via the FLAG-tagged EMC3 verified that the UV-dependent EMC3 crosslinking partner is EMC1. Denaturing IP of EMC1 followed by anti-FLAG immunoblotting further validated this assignment. The EMC1 crosslink is sharply diminished at positions T24^AbK^ and F25^AbK^, but is partially recovered at position F26^AbK^, thereby defining the face of this TMD helix that is adjacent to EMC1 ([Figure 5C](#fig5){ref-type="fig"}).

Similar experiments placing AbK in other parts of EMC3 showed that TMD2, but not TMD3, is near EMC1 ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}; results summarized in [Figure 5D](#fig5){ref-type="fig"}). These results not only validated the trRosetta model for EMC3, but also assigned the position of EMC1's sole TMD within the EM density. The remaining TMD-like density in the EM map was assigned to the TMD of EMC7 and supported by Abk-mediated crosslinks seen from TMD2 of EMC3. Additional crosslinking data between EMC5 and EMC6 supported our overall placements for the TMD regions of EMC subunits, resulting in a provisional model for the membrane domain of EMC ([Figure 5D](#fig5){ref-type="fig"}).

The EM density in the cytosolic domain contains regions not accounted by EMC2 or EMC8/9 ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}). The regions of additional density in the cytosolic vestibule extend from the TMDs of EMC1 and possibly EMC6. Consistent with these being core features of EMC, the C-terminal tail of EMC1 and the N-terminal tail of EMC6 are highly conserved. Most of the remaining density could be fitted with minor adjustments to the trRosetta model for the cytosolic domains of EMC3. In particular, a three-helix bundle formed of the coiled-coil between TMD1 and TMD2 in complex with a helix in the C-terminal tail fit well into a pyramidal density on the backside of EMC2. This three-helix bundle is predicted based on co-evolution analysis using trRosetta. Consistent with this placement, AbK positioned in the EMC3 coiled coil where it approaches the three-helix bundle of EMC4 forms a UV-mediated EMC3-EMC4 crosslink. The remainder of the cytosolic density might correspond to EMC3's C-terminal tail. Thus, EMC2 organizes EMC's membrane subunits via its multi-pronged interactions with EMC1, EMC3, and EMC6, explaining why the membrane domain of EMC falls apart completely in the absence of EMC2 ([@bib74]).

The lumenal region of EMC is almost entirely composed of the lumenal domains of EMC1, EMC7, and EMC10. Predictions of their structures ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) generated models that could be unambiguously docked into the lumenal region of the EM map ([Figure 5E](#fig5){ref-type="fig"}). In these models, EMC1 contains two beta-propellers, while EMC7 and EMC10 each contain a small beta-barrel of different sizes. Using these distinctive features to guide docking, other regions of continuous density could be assigned to other parts of the predicted models with minor adjustments. The most prominent additional feature was a long conserved amphipathic helix flanked by two long unstructured linkers. We assigned this EMC1 helix to a conspicuous density (termed the crossbar) that sits at the interface between the lumen and membrane. Inspection of the density at the plane of the crossbar where the TMDs interact with the lumenal domain shows that EMC does not have a pore across the membrane that connects the cytosolic vestibule to the ER lumen ([Figure 5F](#fig5){ref-type="fig"}).

In sum, all of the membrane-embedded and lumenal density in the EM map could be accounted for by rigid body fitting the independently generated trRosetta models ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). These models were subsequently real-spaced refined into the density using PHENIX. The combination of atomic resolution structures, contact-informed modeling, photocrosslinking, and moderate resolution EM-density allow the positioning of individual subunits to produce a composite EMC structure ([Figure 5---figure supplement 5](#fig5s5){ref-type="fig"}; [Table 3](#table3){ref-type="table"}). The composite structural model accounts for the majority of EMC polypeptides with the exception of the TMD of EMC10 and flexible loops and termini of many subunits.

###### EM refinement statistics.

  ------------------------------- -------
  Resolution for refinement (Å)   6.4
  CC~Mask~                        0.72
  RMS deviations                  
   Bond length (Å)                0.005
   Bond angle (°)                 1.028
  No. of atoms                    9412
  Protein residues                1906
  Ramachandran Outliers (%)       0.49
  Mean B-factors (^2^)            200.0
  MolProbity score                2.77
  Clash score                     31.03
  PDB code                        6Z3W
  ------------------------------- -------

The vestibule leads into a lipid-exposed intramembrane groove {#s2-6}
-------------------------------------------------------------

A TMD substrate in the cytosolic vestibule of EMC needs to access the membrane interior for insertion. Furthermore, any route into the membrane should not only be accessible from the vestibule, but also be separated from the vestibule by a gap exposed to the cytosol. The gap is crucial for release of substrate from EMC; without it, the polypeptide segment between the substrate's TMD and cytosolic domain could not pass into the cytosol. This is analogous to the Sec61 complex, where a gap of \~10 Å separates the cytosolic end of the lateral gate and the ribosome surface surrounding the mouth of the polypeptide exit tunnel ([@bib77]).

The cytosolic vestibule is continuous with a large horseshoe-shaped groove lined by the TMDs of EMC1, EMC3, EMC6, and EMC5 ([Figure 6A](#fig6){ref-type="fig"}; red star in [Figure 5A](#fig5){ref-type="fig"}). The lumenal side of this groove contains the crossbar contributed by EMC1. The groove stretches deep into the membrane and is open laterally toward the lipid bilayer ([Figure 6B](#fig6){ref-type="fig"},). Importantly, the cytosolic side of this groove at the N-terminus of EMC5 is separated from EMC2 by a clear gap of \~9 Å. This region of EMC2 is also predicted to be flexible and could move further away as needed during substrate insertion ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Thus, a substrate TMD in the vestibule could potentially enter this groove and diffuse away from EMC with the cytosolic flanking polypeptide passing through the EMC2-EMC5 gap. Future mutagenesis experiments of groove-lining residues and site-specific crosslinking to substrates are needed to validate the proposed pathway of insertion.

![The cytosolic vestibule leads into an intramembrane groove.\
(**A**) The cytosolic vestibule in EMC2•EMC9 (grey surface) is contiguous with a horseshoe-shaped intramembrane groove lined by the TMDs of EMC1, EMC3, EMC5, and EMC6. The lumenal domain of EMC and the TMDs of EMC7 and EMC4 are not shown for clarity. (**B**) Fitting the composite EMC model (red) into cryo-EM density (blue) reveals a \~ 6--12 Å gap between the cytosolic and membrane domains of EMC. A substrate with a TMD in the intramembrane groove can be released from EMC with the cytosolic flanking polypeptide passing through this gap.](elife-57887-fig6){#fig6}

Discussion {#s3}
==========

TMDs are typically \~15--25 amino acid long with mostly hydrophobic side chains. Our analysis of EMC leads to a plausible mechanistic model for how it moves TMDs close to the N- or C-terminus of a protein from the aqueous cytosol to the membrane interior ([Figure 7A](#fig7){ref-type="fig"}). The partially hydrophobic character of a TMD favours binding to the cytosolic vestibule formed by the EMC2•EMC8 or EMC2•EMC9 complex. This vestibule is constitutively open to the cytosol, is shallow, and is only moderately hydrophobic. In these respects, EMC's vestibule differs from the targeting factors SRP and Get3, both of which have deeper, more hydrophobic grooves. These differences reflect their distinct roles: SRP and Get3 ferry TMDs through the cytosol to the membrane, while EMC engages TMDs that are already at the membrane. Thus, EMC2•EMC9 does not need to fully cover the TMD or bind to it stably; it instead serves as a portal of entry. Stable substrate binding to EMC2•EMC9 is not needed and might even be detrimental by impeding TMD release into the membrane.

![Model for EMC-mediated TMD insertion.\
(**A**) TMDs follow a gradient of increasing hydrophobicity from the cytosol through EMC and into the lipid bilayer. TMDs first enter the cytosolic vestibule formed by either the EMC2•EMC8 or EMC2•EMC9 complex. This vestibule leads into an intramembrane groove that is laterally open toward the lipid bilayer. (**B**) The ribosome-Sec61 complex is depicted with EMC at the same scale in the same membrane plane. The minimum distance from the Sec61 lateral gate to the intramembrane groove of EMC is \~110 Å. This implies that EMC can only mediate TMD insertion before ribosomes bind to Sec61 or if the polypeptide downstream of a TMD can span this distance. EMC cannot capture TMDs at the Sec61 lateral gate.](elife-57887-fig7){#fig7}

EMC, like SRP and Get3, contains a conserved intramolecular 'placeholder' that sits in the substrate binding site and must be displaced by substrate. Hence, substrates that engage EMC2•EMC9 must not only be more favourable within the vestibule than in the aqueous environment, but also more favourable in the vestibule than the placeholder. These constraints may provide a degree of specificity for potential TMDs and discriminate against hydrophilic sequences. The conformation of substrates within the vestibule is not known, but might not be a helix in contrast to TMDs bound by SRP or Get3. This is because helix formation of a TMD occurs when shielding the polypeptide backbone is more favourable than exposing it to solvent. Because the vestibule is shallow, exposed to aqueous solvent, and has appreciable hydrophilic surfaces, the nascent TMD is likely to be unstructured when it first binds. This mode of binding might allow different regions of the vestibule to accommodate different types of TMDs. Furthermore, by exposing the backbone amides and carbonyls, even rather hydrophobic TMDs could be temporarily accommodated within a partially hydrophilic vestibule.

From the vestibule, the polypeptide has two points of egress: back toward the cytosol or into the intramembrane groove. This choice would be influenced by the polypeptide's properties. Hydrophilic polypeptides that transiently sampled the groove spuriously would diffuse back into the cytosol. Similarly, internal segments of polypeptides with large domains on either side would be sterically disfavoured from entering the groove. In this way, access into the groove serves as a filter that preferentially favors entry of terminal TMDs. Regardless of the precise register of the TMDs that form the intramembrane groove, its surface is more hydrophobic than the cytosolic vestibule. We therefore posit that polypeptide movement into the groove would be accompanied by helix formation. We expect substrate residence time in the groove would be minimal because it is open to the lipid bilayer. It is likely that TMD movement into the groove, helix formation, and partitioning into the membrane interior occur in rapid succession. Thus, the cytosol, vestibule, groove, and membrane interior are connected via a gradient of hydrophobicity that a TMD follows during its energy-independent insertion by EMC ([Figure 7A](#fig7){ref-type="fig"}).

The topology of the TMD would be influenced by steric constraints imposed by its flanking regions. Because the groove is not open toward the lumen, the side of the substrate containing only a short flexible segment can be translocated while the side with a bulky domain cannot. Translocation of the short terminus could be promoted despite the absence of a trans-bilayer pore by thermodynamically favorable release of a TMD into the lipid environment ([@bib19]). This driving force can facilitate translocation of up to \~100 amino acid long polypeptide segments in the absence of a translocon ([@bib10]). In cases where both sides are short (e.g., very small single-TMD proteins), one orientation might be favoured over the other by flanking charges on the substrate being interpreted by charged residues on EMC.

It is noteworthy that EMC2 at the entry point into the intramembrane groove contains well-conserved solvent-exposed basic amino acids (see [Figure 2B](#fig2){ref-type="fig"}) such as Arg26 and Arg91. Furthermore, the ordered cytosolic tail of EMC1 at this key junction contains four conserved basic residues, at least some of which would face the vestibule. Finally, a conserved basic residue at position six in EMC5, and possibly its N-terminus, may also contribute net positive charge in this region. This enrichment of positive charge (and relatively fewer exposed negative charges) would disfavor entry into the groove of polypeptide segments that are enriched in basic amino acids. Such a mechanism would select against mitochondrial TA proteins, cleavable signal peptides, and N~cyt~ signal anchors. In each case, these otherwise suitable EMC substrates (based on their terminal location and hydrophobicity) are enriched in basic amino acids in the short unstructured domain flanking the hydrophobic region ([@bib6]; [@bib16]; [@bib75]; [@bib36]). Conversely, bona fide EMC substrates (ER-targeted TA proteins and N~exo~ signal anchors) are typically dis-enriched in basic amino acids in the translocated tail. Thus, the mechanism of substrate selection by EMC might be part of the explanation for the 'positive-inside rule', a long-observed preference for positive flanking charges facing the cytosol ([@bib23]). This is an important area for future investigation.

The architecture and dimensions of EMC have major implications for when it acts during co-translational insertion of N-terminal TMDs and how it could function as a putative chaperone. EMC cannot feasibly approach closer than \~100 Å to a ribosome-bound Sec61 complex ([Figure 7B](#fig7){ref-type="fig"}). This means that EMC can act co-translationally on TMDs only before the ribosome docks on the Sec61 complex or only after at least \~100 Å of polypeptide downstream of the TMD has emerged from the ribosomal tunnel. Because ribosome-nascent chain complexes in which a TMD has just emerged from the ribosome can be inserted in an EMC-dependent manner, we have postulated that EMC acts after SRP-mediated targeting but before ribosomes bind to the Sec61 complex ([@bib14]). Due to SRP's position at the ribosome exit tunnel ([@bib29]; [@bib58]; [@bib78]), Sec61 cannot engage its binding site unless SRP releases the TMD and dissociates from the ribosome. Thus, there is a brief window when a TMD is available for EMC-mediated insertion before Sec61 binds to its position at the exit tunnel ([@bib33]; [@bib38]). We posit that this time constraint helps minimize inappropriate insertion of N-terminal TMDs intended for the N~cyt~ topology so they can be subsequently inserted by the Sec61 complex.

Although the intramembrane groove is well suited to serve as a chaperone for a single TMD, such a function seems unlikely to occur adjacent to the Sec61 translocon as proposed on the basis of ribosome profiling experiments ([@bib65]). Co-translational engagement of EMC by TMDs emerging from the ribosome-Sec61 complex could only occur once a TMD can diffuse at least 100 Å away. The very rigid structure of the EMC2•EMC9 complex and the absence of subcomplexes lacking these proteins makes it unlikely that the steric constraints shown in [Figure 7B](#fig7){ref-type="fig"} could be overcome. Furthermore, the intramembrane groove is sufficiently large to house one TMD, and possibly a second just outside the groove. This means that EMC is not likely to bind multiple TMDs simultaneously. Thus, a chaperone function would seem limited to post-translationally engaging an isolated TMD that has not yet assembled with its intra- or inter-molecular partners. Direct evidence for this function is currently lacking, but merits future study.

The role of the lumenal domain of EMC is currently unclear. The simplest possibility is that it serves a crucial structural role in stabilizing the seven integral membrane subunits while sealing the intramembrane groove toward the lumen. Maintaining the intramembrane groove configuration might be energetically unfavourable without structural caps on both sides. Other examples of proteins with a large lipid-exposed groove have most or all of their TMDs within a single polypeptide in contrast to EMC's multi-protein assembly ([@bib41]; [@bib51]; [@bib55]; [@bib59]). Thus, the lumenal domain, like EMC2, might nucleate EMC assembly, an early structural solution that was maintained across all eukaryotes.

Our proposed mechanism for EMC-mediated TMD insertion is conceptually similar to how the prokaryotic protein YidC is thought to function ([@bib17]). YidC is a much simpler protein with a 5-TMD core whose arrangement forms an intramembrane 'hydrophobic slide' lined by TMD1, TMD2, and TMD5 ([@bib41]). The hydrophobic slide in YidC is appreciably smaller than the intramembrane groove in EMC and could not house a substrate TMD helix without conformational changes. Nevertheless, biochemical evidence supports the notion that substrate TMDs are near the hydrophobic slide during insertion ([@bib37]; [@bib88]). Our structural model for the EMC3 subunit is consistent with an evolutionary relationship to YidC ([@bib4]). Notably however, EMC3 in our model is oriented such that the surface corresponding to YidC's hydrophobic slide is opposite to the surface lining EMC's intramembrane groove (see [Figure 5D](#fig5){ref-type="fig"}). This observation raises the possibility that the putative hydrophobic slide in EMC3 might be an alternative or additional route for substrate TMD insertion.

One way this could occur without risk of substrate entanglement in EMC is if the TMD approaches the hydrophobic slide from behind the EMC2•EMC9 vestibule. Upon insertion into the hydrophobic slide, the TMD would then release from EMC in the same direction from which it approached. Unlike in YidC however, access to lipid from the hydrophobic slide in EMC3 is partially occluded by EMC4 ([Figure 5D](#fig5){ref-type="fig"}). Thus, insertion via this alternative 'backside' route may require conformational changes to create more space between EMC3, EMC4, and EMC6 so substrates can enter the lipid bilayer.

Regardless of the exact route(s) of insertion through EMC, it appears that a simplified insertase originating from a YidC-like protein ([@bib8]) has been elaborated during evolution to form EMC. As Get1 appears to be a homolog of EMC3, the Get1/Get2 complex may be a simplified version of EMC that co-opted a different binding partner. High resolution structures of EMC's membrane region and the Get1/Get2 complex, together with structure-guided mutagenesis and substrate crosslinking experiments, will be important for fully elucidating and comparing their potentially shared mechanisms.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                           Designation                                    Source or reference        Identifiers                                                                         Additional information
  (species) or resource                                                                                                                                                                                 
  --------------------------------------- ---------------------------------------------- -------------------------- ----------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Strain, strain background (*E. coli*)   BL21 NEB Express competent cells               New England Biolabs        Cat\# C2523                                                                         

  Cell line (*Homo-sapiens*)              HEK293 TRex EMC5-FLAG                          [@bib26]                   MBP04                                                                               EMC5-FLAG (see below) integrated into FRT site of HEK293 TRex-Flp-in cell line. Adapted for growth in FreeStyle suspension media

  Cell line (*Homo-sapiens*)              HEK293 TRex GFP-P2A-RFP-SQS                    [@bib13]                                                                                                       

  Cell line (*Homo-sapiens*)              HEK293 TRex OPRK-GFP-P2A-RFP                   [@bib13]                                                                                                       

  Cell line (*Homo-sapiens*)              HEK293T                                        ATCC                       ATCC-CRL-3216                                                                       

  cell line (*Homo-sapiens*)              U2OS Flp-in TRex                               [@bib74]                                                                                                       

  Cell line (*Homo-sapiens*)              U2OS Flp-in TRex ∆EMC2                         [@bib74]                                                                                                       EMC2 disrupted using CRISPR-Cas9

  Antibody                                ANTI-FLAG M2 Affinity Gel (mouse monoclonal)   Sigma                      Cat\# A4596                                                                         

  Antibody                                Mouse monoclonal ANTI-FLAG M2-HRP conjugated   Sigma                      Cat\# A8592, RRID:[AB_439702](https://scicrunch.org/resolver/AB_439702)             WB (1:10000)

  Antibody                                Rabbit polyclonal EMC1                         Thermo Fisher Scientific   Cat\# A305-605A-M, RRID:[AB_2782763](https://scicrunch.org/resolver/AB_2782763)     WB (1:1000), IP (0.1 µg/sample)

  Antibody                                Rabbit polyclonal EMC4                         Thermo Fisher Scientific   Cat\# A305-752A-M, RRID:[AB_2782909](https://scicrunch.org/resolver/AB_2782909)     IP (0.4 µg/sample)

  Antibody                                Rabbit polyclonal EMC4 (TMEM85)                Abcam                      Cat\# ab123719, RRID:[AB_10951091](https://scicrunch.org/resolver/AB_10951091)      WB (1:1000)

  Antibody                                Rabbit polyclonal EMC5 (MMGT1)                 Abcam                      Cat\# ab174366, RRID:[AB_2750837](https://scicrunch.org/resolver/AB_2750837)        WB (1:1000)

  Antibody                                Rabbit polyclonal EMC6 (TMEM93)                Abcam                      Cat\# ab84902, RRID:[AB_1925516](https://scicrunch.org/resolver/AB_1925516)         WB (1:1000)

  Antibody                                Rabbit polyclonal EMC7 (C15orf24)              Proteintech                Cat\# 27550--1-AP                                                                   WB (1:3000)

  Antibody                                Rabbit polyclonal EMC7                         Thermo Fisher Scientific   Cat\# A305-678A-M, RRID:[AB_2782836](https://scicrunch.org/resolver/AB_2782836)     WB (1:1000)

  Antibody                                Rabbit polyclonal Calnexin N-terminus          Enzo Life Sciences         Cat\# ADI-SPA-865, RRID:[AB_10618434](https://scicrunch.org/resolver/AB_10618434)   WB (1:5000)

  Antibody                                Rabbit polyclonal HA tag                       This paper                 Custom antibody raised against HA peptide conjugated to KLH.                        WB (1:5000)

  Recombinant DNA reagent                 pET28a-6xHIS-SUMO-EMC2                         This paper                                                                                                     Human EMC2, Residues 1--297

  Recombinant DNA reagent                 pET21-EMC2-6xHIS                               This paper                                                                                                     Human EMC2, Residues 1--297

  Recombinant DNA reagent                 pET28a-6xHIS-SUMO-EMC8                         This paper                                                                                                     Human EMC8, Residues 1--210

  Recombinant DNA reagent                 pET21-EMC9-6xHIS                               This paper                                                                                                     Human EMC9, Residues 1--208

  Recombinant DNA reagent                 pET21-EMC2-6xHIS                               This paper                                                                                                     Human EMC2, Residues 11--274, for crystallization

  Recombinant DNA reagent                 pET21-EMC9-6xHIS                               This paper                                                                                                     Human EMC9, Residues 1--200\
                                                                                                                                                                                                        for crystallization

  Recombinant DNA reagent                 pET28a-6xHIS-ULP                               This paper                                                                                                     Yeast ULP1 protease (Uniprot: Q02724), Residues 403--621, for SUMO cleavage

  Recombinant DNA reagent                 SEC61-SQS(amber)−3 F4                          [@bib26]                                                                                                       T7-based PURExpress plasmid (New England Biolabs), SQS TMD residues 378--410, Amber mutation at F389

  Recombinant DNA reagent                 SQS(amber)−3 F4                                This paper                                                                                                     T7-based PURExpress plasmid (New England Biolabs), SQS TMD residues 378--410, Amber mutation at F389

  Recombinant DNA reagent                 Clonetech-GFP-P2A-RFP-SQS                      [@bib26]                                                                                                       

  Recombinant DNA reagent                 pcDNA5-EMC2-3xHA                               This paper                                                                                                     Human EMC2, Residues1--297, Tet operator removed with Sac1

  Recombinant DNA reagent                 pEVOL-pBpF                                     [@bib11]                                                                                                       

  Recombinant DNA reagent                 pcDNA5/FRT/TO-EMC3-Xamb-3xFLAG                 This paper                                                                                                     Human EMC3 with an amber codon at position X and a C-terminal 3xFLAG tag. Individual constructs where X = 23, 24, 25, 26, 71, 124, 125, 126, 127, 172, 173, 174, and 175 were produced.

  Recombinant DNA reagent                 pcDNA5/FRT/TO- EMC5-Xamb-3xFLAG                This paper                                                                                                     Human EMC5 with an amber codon at position X and a C-terminal 3xFLAG tag. Individual constructs where X = 14, 15, 16, 17, 54, 55, 56, and 57 were produced.

  Recombinant DNA reagent                 pcDNA5/FRT/TO-3xFLAG-EMC6-Xamber               This paper                                                                                                     Human EMC6 with an amber codon at position X and an N-terminal 3xFLAG tag. Individual constructs where X = 58, 59, 60, 61, 94, 95, 96, and 97 were produced.

  Recombinant DNA reagent                 pAS-Pyl-AF                                     This paper                                                                                                     *Methanosarcina mazei* pyrrolysyl-tRNA synthetase with Y306A/Y384F mutations and its cognate tRNA carrying a U25C mutation

  Recombinant DNA reagent                 pcDNA5/FRT/TO-3xHA-EMC4                        This paper                                                                                                     Human EMC4 with an N-terminal 3xHA tag

  Recombinant DNA reagent                 pcDNA5/FRT/TO-EMC4-3xHA                        This paper                                                                                                     Human EMC4 with a C-terminal 3xHA tag

  Sequence-based reagent                  siRNA \#1 against EMC3                         Ambion                     Custom synthesis                                                                    GGCACUAGAUGAUGUCGAAtt

  Sequence-based reagent                  siRNA \#2 against EMC3                         Ambion                     Custom synthesis                                                                    CCUACUAUGUUGACAGACAtt

  Sequence-based reagent                  siRNA \#1 against EMC8                         Ambion                     Custom synthesis                                                                    AGAUCAUAGCUACGUGAUUtt

  Sequence-based reagent                  siRNA \#2 against EMC8                         Ambion                     Custom synthesis                                                                    GCUGGUUAUUAUCAAGCUAtt

  Sequence-based reagent                  siRNA \#1 against EMC9                         Ambion                     Custom synthesis                                                                    GUACUUAUUAUGUUGGAUAtt

  Sequence-based reagent                  siRNA \#2 against EMC9                         Ambion                     Custom synthesis                                                                    AUGCAGCUGUGAACGAUCAtt

  Peptide, recombinant protein            3X FLAG Peptide                                Sigma-Aldrich              Cat\# F4799                                                                         

  Peptide, recombinant protein            Human SGTA                                     [@bib60]                                                                                                       

  Peptide, recombinant protein            Human CaM                                      [@bib60]                                                                                                       

  Peptide, recombinant protein            Human EMC2                                     This paper                                                                                                     Purified from NEB BL21express cells

  Peptide, recombinant protein            Human EMC8                                     This paper                                                                                                     Purified from NEB BL21express cells

  Peptide, recombinant protein            Human EMC9                                     This paper                                                                                                     Purified from NEB BL21express cells

  Peptide, recombinant protein            ULP1 Protease                                  This paper                                                                                                     Purified from NEB BL21express cells

  Commercial assay or kit                 PURE in vitro translation system               [@bib60]                                                                                                       

  Chemical compound, drug                 deoxy big CHAP (DBC)                           Anatrace                   Cat\# 256455                                                                        

  Chemical compound, drug                 Lauryl Maltose Neopentyl Glycol (LMNG)         Anatrace                   Cat\# NG310 5 GM                                                                    

  Chemical compound, drug                 Bpa                                            BACHEM                     Cat\# 4017646                                                                       

  Chemical compound, drug                 AbK                                            Iris Biotech GmbH          Cat\# HAA3110                                                                       

  Software, algorithm                     CryoSPARC version 2.12.4.                      [@bib50]                   RRID:[SCR_016501](https://scicrunch.org/resolver/SCR_016501)                        

  Software, algorithm                     UCSF ChimeraX\                                 [@bib24]                   RRID:[SCR_015872](https://scicrunch.org/resolver/SCR_015872)                        
                                          Version 1.0                                                                                                                                                   

  Software, algorithm                     trRosettta\                                    [@bib87]                                                                                                       
                                          Structure Prediction Server                                                                                                                                   

  Software, algorithm                     PHENIX\                                        [@bib1];\                  RRID:[SCR_014224](https://scicrunch.org/resolver/SCR_014224)                        
                                          Version 1.17                                   [@bib2]                                                                                                        

  Software, algorithm                     *Coot*\                                        [@bib18]                   RRID:[SCR_014222](https://scicrunch.org/resolver/SCR_014222)                        
                                          Version 0.9-pre                                                                                                                                               

  Software, algorithm                     XDS\                                           [@bib35]                   RRID:[SCR_015652](https://scicrunch.org/resolver/SCR_015652)                        
                                          Version 20190315                                                                                                                                              

  Software, algorithm                     PyMol\                                         DeLano Scientific LLC      RRID:[SCR_000305](https://scicrunch.org/resolver/SCR_000305)                        
                                          Version 2.1                                                                                                                                                   

  Software, algorithm                     DIALS\                                         [@bib85]                                                                                                       
                                          Version 2.2                                                                                                                                                   

  Software, algorithm                     BLEND\                                         [@bib22]                                                                                                       
                                          CCP4i 7.0.076                                                                                                                                                 

  Software, algorithm                     Pointless\                                     [@bib21]                   RRID:[SCR_014218](https://scicrunch.org/resolver/SCR_014218)                        
                                          CCP4i 7.0.076                                                                                                                                                 

  Software, algorithm                     Aimless\                                       [@bib20]                   RRID:[SCR_015747](https://scicrunch.org/resolver/SCR_015747)                        
                                          CCP4i 7.0.076                                                                                                                                                 

  Software, algorithm                     SHELXD\                                        [@bib63]                                                                                                       
                                          Version 2013/2                                                                                                                                                

  Software, algorithm                     FlowJo\                                        FlowJo, LLC                RRID:[SCR_008520](https://scicrunch.org/resolver/SCR_008520)                        
                                          Version 9.9.6                                                                                                                                                 

  Software, algorithm                     FlexEM                                         [@bib71]                                                                                                       

  Other                                   1.2/1.3 UltrAu Foil grids                      Quantifoil                 Direct Order Form System                                                            

  Other                                   Au 200 2/2 grids                               Quantifoil                 Direct Order Form System                                                            
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Protein expression and purification {#s4-1}
-----------------------------------

Bacterial over-expression plasmids for EMC2, EMC8, EMC9, SGTA, calmodulin, subsequent point mutations, and amber suppression mutations were produced by standard molecular biology techniques and listed in the Key Resources Table. Proteins were expressed in *E. coli *BL21 NEB express cells at 18°C for 18 hr following induction with 0.5 mM IPTG at an OD 600 of 0.6. For non-natural amino acid incorporation, amber codons were introduced at desired sites using site directed mutagenesis. Constructs were co-expressed with pEVOL-pBpF ([@bib11]) in *E. coli* BL21 NEB express cells at 37°C. At OD 600 of 0.3, 0.2% L-arabinose was added to cultures and continued to grow to an OD 600 of 0.6 and cultures were cooled to 16°C. Once cultures were cooled, 0.15 mM IPTG and 1 mM benzoyl-phenylalanine (from a 1 M stock in 1 M NaOH) was added. Cells were then cultured at 16°C overnight. For both standard and amber suppression protein expression, cells were harvested via centrifugation, resuspended in ice cold Ni^2+^-NTA buffer A (25 mM Tris pH 8.4, 500 mM NaCl, 20 mM Imidazole), lysed using sonication at 4°C, and subjected to centrifugation at 39,000 x g for 1 hr at 4°C. The supernatant containing hexahistidine-tagged proteins was passed over a column of Ni^2+^-NTA matrix (Qiagen) at 0.5 mL matrix/1 L of culture. The matrix was washed with 20 column volumes of Ni^2+^-NTA buffer A and eluted in a minimum of 3 column volumes using Ni^2+^-NTA buffer A supplemented with imidazole to a final concentration 500 mM. Samples were buffer exchanged into 25 mM HEPES pH 7.5, 100--400 mM NaCl (depending on the protein) with either PD-10 or HiPrep 26/10 desalting columns (GE Healthcare). SGTA, calmodulin, and EMC amber suppression samples for in vitro assays were used directly and subsequently were supplemented with 10% glycerol and flash frozen in liquid nitrogen. EMC8 expression required an amino terminal SUMO solubilization tag, which was subsequently cleaved using ULP1 protease overnight at 4°C. Excess His-tagged SUMO and His-tagged ULP1 protease were removed via passage through a column of Ni^2+^-NTA matrix. EMC2, EMC8, and EMC9 were concentrated and subjected to gel filtration using a GE 200 16/60 liquid chromatography column equilibrated in 25 mM HEPES pH 7.5 and 400 mM NaCl. Complex formation of EMC2•EMC8 or EMC2•EMC9 complexes was achieved by mixing a 1 to 1.2 molar ratio of EMC2 and either EMC8 or EMC9. Excess EMC8 or EMC9 was removed with gel filtration as indicated above.

Size-Exclusion chromatography coupled to Multi-Angle light scattering {#s4-2}
---------------------------------------------------------------------

Protein samples at 1 mg/mL (15--40 mM) were injected onto an S200 10/300 Increase SEC column (GE, Marlborough, MA), equilibrated with 25 mM HEPES pH 7.5, 400 mM NaCl. The SEC column was coupled to a static 18-angle light scattering detector (DAWN HELEOS-II) and a refractive index detector (Optilab T-rEX) (Wyatt Technology, Goleta, CA). Data were collected every second at a flow rate of 0.5 mL/min. Data analysis was carried out using ASTRA VI, yielding the molar mass for each sample. The light scattering detectors were normalized and data quality were assessed by testing a BSA standard (Pierce).

Microscale thermophoresis {#s4-3}
-------------------------

Solvent exposed cysteine labeling of EMC2 was conducted with 100 µM EMC2 and 120 µM maleimide OG-488 (Molecular Probes, Eugene, OR) for 30 min on ice. Excess dye was removed from the labeling reaction with a NAP-5 column (GE, Marlborough, MA) pre-equilibrated with 25 mM HEPES pH 7.5, 500 mM NaCl. The labeling efficiency ranged from 55--65%. The concentration of EMC2•OG-488 was fixed at 50 nM and a dilution series of EMC8 or EMC9 ranging from 4 nM to 150 µM was used in the hydrophilic treated capillaries (NanoTemper Technologies). A Monolith NT.115 instrument (NanoTemper Technologies) was used with a 50% LED power and laser pulses at both 60% and 100% power. Data were analyzed using the NT Analysis software (NanoTemper Technologies).

Crystallization of EMC2•EMC9 complex {#s4-4}
------------------------------------

EMC2•EMC9 complex comprising EMC2 residues 11--274 (of the 297 residue full length protein) and EMC9 residues 1--200 (of the 208 residue full length protein) were gel filtered into a buffer containing 25 mM Tris pH 8.5 and 400 mM NaCl. Protein at a concentration of 30 mg/mL was screened through sitting drop vapor diffusion using 200 nL protein mixed with 200 nL of reservoir solution and incubated at 20°C. Initial crystals were optimized via hanging drop vapor diffusion by mixing 800 nL of protein (30 mg/mL) and 600 nL reservoir solution followed by incubation at 20°C. The crystal used for experimental phasing had a reservoir solution containing 28% PEG4000, 0.1 M Tris pH 8.3, and 0.2 M lithium sulfate. Crystals appeared and reached maximum dimensions without visual defects between 1--2 days. Crystals for experimental phasing were transferred to reservoir solution containing 20% glycerol for cryoprotection. Crystals used for native data set collection were grown in a reservoir solution containing 34% PEG4000, 0.1 M Tris pH 8.3, and 0.2 M lithium sulfate. Crystals for native collection were harvested within 24 hr directly from the drop by adding 4 µL of reservoir solution containing 20% ethylene glycol and incubating 1 min. Cryopreserved crystals were flash frozen in liquid nitrogen.

Crystallographic data collection and analysis {#s4-5}
---------------------------------------------

Data were collected on EMC2•EMC9 crystals using I23 long-wavelength beamline at Diamond. Four native sulfur-SAD experiments with varied kappa goniometer orientation were conducted with a single crystal and each data set contained 3600 images collected at λ = 2.755 Å with 0.1° oscillations on a curved Pilatus 12M detector. Images were integrated and scaled with XDS and XSCALE ([@bib35]). The substructure consisting of 27 sulfur sites was solved using SHELXD ([@bib63]) and phases were obtained with Autosol ([@bib1]). The initial model was built manually and refined using *Coot* ([@bib18]) and PHENIX ([@bib1]) respectively. The space group was P2~1~2~1~2~1~ and a single EMC2•EMC9 molecule was observed in the asymmetric unit.

A native non-isomorphous P2~1~2~1~2~1~ dataset was collected collected at I03 with a λ = 0.9763 Å, 3600 images with a 0.1° oscillation on an Eiger2 XE 16M detector. Data reduction was carried out with DIALS where four lattices offset by less than 5° were determined using multi-lattice processing ([@bib85]), and each of the four lattices contained an equivalent number of reflections. The deconvolved datasets were analyzed in BLEND ([@bib22]) and merged/scaled using Pointless ([@bib21]) and Aimless ([@bib20]). The structure was determined by molecular replacement using the software package PHENIX ([@bib1]). Iterative rounds of building and refinement were completed using *Coot* ([@bib18]) and PHENIX ([@bib2]), which resulted in the final model (PDB: 6Y4L). Data collection and refinement statistics are summarized in [Table 1](#table1){ref-type="table"}. Illustrations were made in Pymol versions 1.8.6 and 2.3.2 (Schrodinger, LLC). Surface chemical properties and conservation were displayed as previously described ([@bib5]; [@bib28]).

Mammalian cell culture {#s4-6}
----------------------

All cell lines were cultured in DMEM containing 10% fetal calf serum and 2 mM L-glutamine. HEK293 T-REx Flp-In cells overexpressing EMC5-FLAG have been described ([@bib26]). Wild type U2OS Flp-In TRex cells and ΔEMC2 U2OS Flp-In TRex cells have been characterized previously ([@bib74]). HEK293T cells were originally from ATCC (ATCC CRL-3216). Cell line identities were verified by a combination of an integrated Frt site and doxycycline inducibility (distinctive to Flp-in T-Rex cells), by antibiotic resistance markers, and by immunoblotting for the product of knockout alleles. Further genetic analysis was not performed. Cells were checked approximately monthly for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza) and found to be negative.

Purification of native mammalian EMC {#s4-7}
------------------------------------

40 g pellets of suspension adapted HEK293 T-REx Flp-In cells overexpressing EMC5-FLAG were solubilized in 40 mL of 2x solubilization buffer \[100 mM HEPES pH 7.4, 400 mM NaCl, 4 mM MgAc~2~, 1.6% deoxy big CHAP (DBC; Merck -- 256455)\] for 1 hr with gentle shaking on ice. All subsequent steps apart from FLAG elution were conducted on ice or at 4°C. Solubilized cells were clarified for 20 min at 21,000 x g at 4°C and incubated for 1 hr with 1 mL bed volume of anti-FLAG M2 affinity gel (Sigma A4596) which had been pre-equilibrated in DBC wash buffer (0.3% DBC, 50 mM HEPES pH 7.4, 200 mM NaCl, 2 mM MgAc~2~). FLAG resin was collected by centrifugation (5 min at 1500 x g) and washed twice with 4 mL DBC wash buffer. Resin was transferred to 10 mL gravity flow column and washed with 3 × 8 mL of 0.1% Lauryl Maltose Neopentyl Glycol (LMNG) wash buffer (0.1% LMNG, 50 mM HEPES pH 7.4, 200 mM NaCl, 2 mM MgAc~2~) allowing 10 min between washes to permit detergent exchange. Resin was then washed with 3 × 8 mL of 0.01% LMNG wash buffer (0.01% LMNG, 50 mM HEPES pH 7.4, 200 mM NaCl, 2 mM MgAc~2~) allowing 10 min between washes for detergent exchange. Two FLAG elutions were conducted for 25 min each at room temperature by incubating the resin in 2 mL of FLAG elution buffer (0.01% LMNG, 50 mM HEPES pH 7.4, 200 mM NaCl, 2 mM MgAc~2~, 0.25 mg/mL 3X FLAG peptide -Sigma F4799) with gentle end-over-end mixing. Combined FLAG elutions were diluted with 4 mL low-salt dilution buffer (0.01% LMNG, 50 mM HEPES pH 7.4, 2 mM magnesium acetate) and were bound to 150 µL bed volume of fast-flow SP sepharose, which had been pre-equilibrated with 2 mL ion exchange buffer A (0.01% LMNG, 50 mM HEPES pH 7.4, 50 mM sodium chloride, 2 mM magnesium acetate). SP sepharose was washed with 3 × 1 mL of ion exchange buffer A before 3 × 150 µL rounds of elution in ion exchange buffer B (0.01% LMNG, 50 mM HEPES pH 7.4, 400 mM sodium chloride, 2 mM magnesium acetate). The first elution was run over the resin twice and the resulting fractions were checked by A280. The peak fraction was then centrifuged for 30 min at 175,000 x g to remove insoluble aggregates.

Cryo-EM sample preparation and data acquisition {#s4-8}
-----------------------------------------------

Grid preparation consists of adding 3 µL of mammalian EMC complex at a concentration of 0.8--0.9 mg/mL to Quantifoil 1.2/1.3 UltrAu Foil grids or Quantifoil gold Au 200 2/2 grids. The Quantifoil 1.2/1.3 UltrAu Foil grids or Quantifoil gold Au 200 2/2 grids were first hydrophilized using a Fischione model 1070 plasma cleaner with a 9:1 ratio of Argon to Oxygen for 2 min and 30 s respectively. Grids were blotted for 9 s and plunged into liquid ethane using a Leica EM GP2 plunge freezer at 100% humidity. Particles were screened on a Technai F20 at 200 kV and data was collected on two FEI Titan Krios microscopes operating at 300 kV and equipped with Gatan K2 summit direct electron detectors, energy filters and volta phase plates. Data were collected at pixel sizes between 1.18 and 1.39 Å per pixel. Exposures were between 5 and 11 s long resulting total accumulated dose of 38 to 45 e^-^/Å^2^ and were fractioned into 25 to 44 frames. All data were collected using FEI's EPU software at the MRC-LMB or eBIC.

Cryo-EM data processing {#s4-9}
-----------------------

Cryo-EM data processing was performed in the CryoSPARC processing suite ([@bib50]) using version 2.12.4. Initially five independent datasets were processed individually. Movies were motion corrected using multi-patch motion correction and CTF values estimated using multi-patch CTF estimation in CryoSPARC. Particles were picked using a blob picker before extraction with a box size of 224 pixels and 2D classification to produce templates for 2D-template based auto picking. Picked particles were subject to 2D and 3D reference-free classification and selected particles were refined using non-uniform refinement and local resolution estimation in CryoSPARC. Maps from datasets with differing nominal pixel sizes were then re-scaled to a range of pixel sizes and matched to a reference map in UCSF Chimera, yielding a cross correlation coefficient ([@bib69]). Titration of these cross correlation values was used to identify an optimal nominal pixel size relative to the reference dataset ([@bib84]). The calculated values were used to re-scale the motion corrected micrographs from two datasets to match the nominal pixel size of 1.38 Å per pixel. The re-scaled datasets were then reprocessed as detailed above. Rescaled particles were merged with particles from three datasets originally collected at 1.38 Å per pixel, resulting in a master pool of 405,515 particles, which were subject to reference-free 3D classification. The final dataset of 167,294 particles was subject to non-uniform refinement followed by per-particle CTF refinement. CTF refined particles were subject to a final round of non-uniform refinement followed by local resolution estimation and filtering to produce a final map with a resolution of 6.4 Å. Refinement was limited to a maximum alignment resolution of 6.5 Å to prevent overfitting. During filtering a conservative *ad hoc* B-Factor of −150 was applied to the map to prevent over-sharpening. Full details of processing of individual and merged datasets are provided in [Table 2](#table2){ref-type="table"}.

PURE in vitro translation reactions {#s4-10}
-----------------------------------

A homemade PURE translation system ([@bib64]) was modified to accommodate amber-suppression as previously described ([@bib60]). Changes that enable nearly quantitative amber-suppression are the omission of RF1, use of *E. coli* tRNA purified from a strain over-expressing the amber suppressor tRNA, addition of recombinant amber suppressor tRNA synthetase (Bpa-RS) at 50 µg/mL, and addition of 0.1 mM of the photo-crosslinking non-natural amino acid benzoyl-phenylalanine (Bpa). Translation reactions of 25 µL were supplemented with 10 ng/µL DNA template, 24 µM CaM, 100 nM CaCl~2~, and 2.5 µL ^35^S-methionine (from a stock of \~10 mCi/mL). Reactions were incubated at 37°C for 30 min, returned to ice, and diluted with 35 µL of ice-cold physiologic salt buffer (PSB: 50 mM HEPES pH 7.5, 100 mM KAc, 5 mM MgAc~2~, 100 nM CaCl~2~). Translated products were isolated via sucrose cushion by layering 50 µL of the diluted translation on top of 50 µL PSB supplemented with 20% sucrose. Centrifugation was conducted for 60 min at 55,000 RPM in a TLS-55 rotor with the slowest acceleration and deceleration possible. The top 80 µL of the sample were removed and snap frozen in liquid N~2~ for storage prior to subsequent use in crosslinking reactions.

Bpa crosslinking reactions {#s4-11}
--------------------------

The translation products prepared as described above were diluted 1:4 in reaction buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 100 nM CaCl~2~) and mixed 1:1 with reaction buffer, SGTA, or EMC components at concentrations indicated in the figure legends. Samples were incubated at 37°C for 5 min, returned to ice and UV-irradiated using a UVP B-100 series lamp (UVP LLC) at a distance of 10 cm for a duration of 10 min.

Protease protection assay {#s4-12}
-------------------------

Plasmids encoding human EMC4 with an N- or C-terminal 3xHA tag in the pcDNA5/FRT/TO vector were transiently transfected into HEK293T cells using PEI 'MAX' (Polysciences). At 3 days after transfection, cells were collected, resuspended in ice-cold homogenizing buffer (20 mM HEPES pH 7.4, 250 mM sucrose, 2 mM MgCl~2~, and EDTA-free protease inhibitor cocktail \[Roche\]), and homogenized on ice by 25 passages through a 26-guage needle fitted to a 1 mL syringe. Homogenates were centrifuged at 800 x g for 5 min at 4°C to pellet nuclei and debris, and the postnuclear supernatants were further centrifuged at 4000 x g for 10 min at 4°C to pellet heavy membranes. The supernatants were then subjected to ultracentrifugation at 100,000 x g for 30 min at 4°C, and the resulting microsome pellets were resuspended in ice-cold physiologic salt buffer-2 (50 mM HEPES pH 7.4, 100 mM KOAc, 2 mM MgAc~2~) and placed on ice. Aliquots were left untreated or treated with 0.5 mg/mL of proteinase K in the presence or absence of 0.5% Triton X-100. After a 30 min incubation on ice, the digestion reactions were stopped by incubation with 5 mM PMSF on ice for 5 min and transferred to 10-volumes of boiling SDS lysis buffer (1% SDS and 0.1 M Tris-HCl pH 8.0). Samples were directly analyzed by SDS-PAGE and immunoblotting.

Site-specific photo-crosslinking in mammalian cells {#s4-13}
---------------------------------------------------

Position-specific incorporation of the photo-crosslinking amino acid AbK into proteins in mammalian cells was achieved by amber suppression using the *Methanosarcina mazei* pyrrolysyl-tRNA synthetase (PylRS) and tRNA^Pyl^~CUA~ pair ([@bib3]). Plasmids used for the in vivo amber suppression were constructed as follows. The plasmid SE315 ([@bib49]), which encodes WT PylRS and the U25C mutant of tRNA^Pyl^~CUA~, was modified to express V5-tagged PylRS carrying Y306A and Y384F mutations \[known as PylRS-AF mutant ([@bib86]) instead of WT PylRS. The resultant plasmid was termed pAS-Pyl-AF and used throughout this study. The coding regions of human EMC subunits were inserted into a pcDNA5/FRT/TO vector containing an N-terminal or C-terminal 3xFLAG tag, and the codons for the selected positions were individually mutated to an amber codon in order to allow AbK incorporation. To express AbK-modified EMC subunits, HEK293T cells were co-transfected with pAS-Pyl-AF and an amber codon-containing EMC construct at a ratio of 4:1 using PEI 'MAX' (Polysciences) and were grown for 2 days in the presence of 0.5 mM AbK (Iris Biotech). After washing cells with PBS, ice-cold PBS was added, and photo-crosslinking was induced by placing cells on ice \~12.5 cm away from a UVP B-100 series lamp (UVP LLC) for 15 min. Cells were then harvested, frozen in liquid nitrogen, and stored at −80°C prior to analysis. For immunoprecipitation under non-denaturing conditions, cell pellets were lysed in native IP buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 2 mM MgAc~2~, 1% Triton X-100) supplemented with EDTA-free protease inhibitor cocktail (Roche). Cell lysates were cleared by centrifugation and incubated at 4°C for 1.5--2 hr with anti-FLAG M2 affinity gel (Sigma). After extensive washing with native IP buffer, proteins were eluted with SDS-PAGE sample buffer. Immunoprecipitation was also done under denaturing conditions using antibodies against EMC subunits. For this, cell pellets were resuspended in SDS lysis buffer (1% SDS and 0.1 M Tris-HCl pH 8.0) and heat-denatured at 95°C for \~10 min with occasional vortex mixing. After cooling to room temperature, the denatured lysates were diluted 10-fold with IP buffer (50 mM HEPES pH 7.4, 100 mM NaCl, 1% Triton X-100) and incubated at 4°C for 1.5--2 hr with Protein A agarose beads plus the appropriate antibody, followed by extensive washing with IP buffer and elution with SDS-PAGE sample buffer.

Flow cytometry analysis {#s4-14}
-----------------------

Wild type U2OS Flp-In TRex cells and ΔEMC2 U2OS Flp-In TRex cells ([@bib74]) were used in flow cytometry experiments and were maintained in DMEM supplemented with 10% fetal calf serum and 2 mM L-glutamine. Inverse transfections were conducted as follows: 3 µL GeneJuice (Merk Millipore) was added dropwise to 100 µL Opti-MEM (Gibco), vortexed and incubated at room temperature for 5 min. SQS-reporter DNA (250 ng) and either EMC2 DNA or empty vector (750 ng) were added to the Opti-MEM/GeneJuice mixture, solution was pipetted up and down to mix, and incubated at room temperature for 20 min. Cells were seeded into a six well dish at 40% confluency concurrent with the addition of 100 µL of the transfection/DNA mixture. Cells were grown for 3 days and then detached with trypsin/EDTA in 250 µL volume, neutralized with 500 µL complete media, and pelleted by centrifugation at 5000 x g in a table top centrifuge at 4°C. Cells were washed by resuspension in 500 µL ice cold PBS and re-pelleted as above. Pelleted cells were resuspended in a final volume of 600 µL ice cold PBS and filtered through a 70 µm cell strainer for analysis. Cells were analyzed using a BD LSR II flow cytometer (BD Biosciences, Franklin Lakes, NJ). The flow cytometry experiment and data analysis using FlowJo software packages were conducted as previously described ([@bib32]). Knockdowns of EMC3, EMC8 and EMC9 with siRNAs were for 3 days in HEK 293 Trex cells with stably integrated inducible reporters (GFP-P2A-RFP-SQS or OPRK-GFP-P2A-RFP) using Lipofectamine RNAiMAX reagent (Thermo Fisher). siRNA sequences are available in the Key Resources Table). Expression of the reporters was induced with 1 µg/ml doxycycline for \~20 hr before analysis by flow cytometry performed as described above.

Statistics and reproducibility {#s4-15}
------------------------------

This study did not employ any statistical analysis or comparisons, no grouping, and no power calculations. Biochemical and cell biological experiments include internal controls that were performed as part of the same experiment and are shown within the respective figures. Each result or conclusion from any given figure panel represents one example of at least two biologically independent experiments, both of which contained the same or similar internal controls. No attempts at replication with valid controls failed. Where data are compiled from multiple measurements ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), the number of replicates are indicated in the figure legend with error bars to indicate standard deviation.
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**Acceptance summary:**

The manuscript describes a very detailed structural analysis of the EMC complex that is involved in incorporating N- or C-terminal transmembrane helices into the ER membrane. It describes a combination of x-ray crystallography and cryo-EM as well as cross linking techniques to establish a model of the entire complex despite the relatively low resolution which requires the use of extensive modelling. Overall, the entire procedure is carefully performed and provides an excellent model that explains the structure and function of this important complex.

**Decision letter after peer review:**

Thank you for submitting your article \"The architecture of EMC reveals a path for membrane protein insertion\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Volker Dötsch as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by John Kuriyan as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

In their manuscript Dr Ramanujan S. Hegde and co-workers address the structure and molecular mechanism of EMC, an ER membrane protein complex which comprises ten subunits and facilitates the insertion of some tail anchored (TA)- and certain multipass-membrane proteins. In the latter case only the most aminoterminal transmembrane domain appears to be head first-/Nexo-inserted by EMC, additional domains of the same membrane proteins were suggested to be integrated into the membrane by the Sec61 complex. Therefore, EMC was proposed to mediate membrane insertion of either amino- or carboxy-terminal transmembrane domains which cannot be handled by the Sec61 complex.

The authors employed state of the art methods for the purification of native EMC as well as individual subunits or mutant variants thereof, 3D reconstruction after cryo-electron microscopy, X-ray crystallography, site specific crosslinking, and functional plus additional biochemical assays for the characterization of the purified proteins.

Revisions:

1\) The RMSD value should be given in A, not A squared.

2\) Among the reviewers the evidence for the inner membrane cavity part of the EMC being a slide for TMH integration was discussed. For your information the original suggestion for experimental evidence is included here:

\"To be convincing, the second part needs to be supported by functional data, such as crosslinking of at least the TA model protein to the intramembrane groove (e.g. at low temperature) plus rational design of mutant variants of groove subunits and test of their membrane insertion capacity for the TA model protein in intact cells. Furthermore, even in the presence of such results it would be difficult to unequivocally exclude the chaperone model for EMC function. In my opinion, the latter would require either crosslinking or 3D reconstruction after cryo-EM of nascent multipass-membrane proteins to EMC and Sec61 complex, and the use of EMC mutant variants in studies on the biogenesis of multipass membrane proteins in intact cells, respectively.\"

However, in the discussion it was agreed that no further experiments are needed, but that the authors should make more careful statements (i.e. use the words suggest, hypothesize, etc.) and that a sentence that \"substrate cross linking will be used for validation of the intramembrane groove in future work\" should be added.

3\) Subsection "Functional analysis of the vestibule in the EMC2•EMC9 complex". It is stated that EMC8 or EMC9 alone suppress aggregation of the model TA substrate less than EMC2 alone does. Whilst true, the difference is not huge for EMC8 (roughly two fold difference) so it seems unsafe to conclude that only EMC2 has specific interactions with the substrate. In fact we later find that EMC9/EMC8 forms part of the substrate binding cavity. It is stated in the Figure 1---figure supplement 2 legend that the crosslinks between the TA substrate and EMC2 alone are physiologically relevant but those between the substrate and EMC8 and EMC9 are due to co-aggregation with the substrate. How do the authors know this?

4\) Figure 3. The HLY substitution that perturbs model substrate integration includes the substitution of an amino acid Y191 that has previously been used as a negative control for the BPA crosslinking experiments because it faces away from the binding cavity. It\'s therefore very difficult to infer that substitution of this residue is affecting substrate binding by changing the polarity of the cavity (rather than changing the protein fold).

5\) Figure 1---figure supplement 2. The CaM-substrate adduct should be labelled to assist the reader.

6\) Figure 5B. The rotation between the two views appears to be the opposite direction to that indicated in the figure. I appreciate that this figure is included primarily to show the quality of the model fit to the EM density, but I did struggle to assign the subunits by their colours under the EM density overlay. For example I could not identify EMC1. It might be worth labelling the subunits nearest the viewer on the figure.

7\) Figure 5C. It would be helpful to know where the crosslinking substituted amino acids are on the structure in Figure 5D. Similarly, it would be useful to have the identify (aa number) of all the crosslinking amino acids shown in Figure 5D marked on the figure.

8\) Figure 5D. Where is the raw data for this figure for those substitutions not shown in Figure 5C? I do think it is misleading to draw a crosslinking line from the substituted amino acid to an exact position on the crosslinked partner subunit because the position of the acceptor amino acid has not been confirmed experimentally. Minimally the legend should say that the crosslink is drawn to the closest point in the model (rather than saying \`verified crosslinks\'), but perhaps on the figure these could be shown as arrows not quite reaching the partner subunit.

9\) Figure 1---figure supplement 3. The authors should indicate in the legend that both of the proteins analysed are EMC substrates.

10\) Figure 4. The placeholder density referred to in the subsection "Position of the EMC2•EMC9 subcomplex within native EMC" should be indicated on the figure if it is present. If it is not this should be made clear when referring to it in the text. The text should also refer forward to where this density is discussed in detail (or even better all this discussion should be moved to where the structure of the density is analysed in Figure 5).

11\) Figure 5E. Again I appreciate that this panel is to show the fit of the model to the EM density but I would like to be able to see the model more clearly. I recommend that the authors include another panel/figure showing the model of the lumenal domain in different views.

12\) Figure 5---figure supplement 3. The TM part of EMC3 should be marked because it is not obvious which helices the modelled EMC3 cytoplasmic density should be associated with. Is there support for the fold of the EMC3 three-helix bundle from a co-evolution model? The raw crosslinking data should be shown.

13\) Are there significant parts of the EMC polypeptides that are not included in the model that has been fitted to the EM density?
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Author response

> Revisions:
>
> 1\) The RMSD value should be given in A, not A squared.

Fixed.

> 2\) Among the reviewers the evidence for the inner membrane cavity part of the EMC being a slide for TMH integration was discussed. For your information the original suggestion for experimental evidence is included here:
>
> \"To be convincing, the second part needs to be supported by functional data, such as crosslinking of at least the TA model protein to the intramembrane groove (e.g. at low temperature) plus rational design of mutant variants of groove subunits and test of their membrane insertion capacity for the TA model protein in intact cells. Furthermore, even in the presence of such results it would be difficult to unequivocally exclude the chaperone model for EMC function. In my opinion, the latter would require either crosslinking or 3D reconstruction after cryo-EM of nascent multipass-membrane proteins to EMC and Sec61 complex, and the use of EMC mutant variants in studies on the biogenesis of multipass membrane proteins in intact cells, respectively.\"
>
> However, in the discussion it was agreed that no further experiments are needed, but that the authors should make more careful statements (i.e. use the words suggest, hypothesize, etc.) and that a sentence that \"substrate cross linking will be used for validation of the intramembrane groove in future work\" should be added.

We agree, and this important caveat has been added (subsection "The vestibule leads into a lipid-exposed intramembrane groove"), as well as more cautious language throughout. We have also added an additional paragraph about alternative models of insertion at the end of the revised Discussion.

> 3\) Subsection "Functional analysis of the vestibule in the EMC2•EMC9 complex". It is stated that EMC8 or EMC9 alone suppress aggregation of the model TA substrate less than EMC2 alone does. Whilst true, the difference is not huge for EMC8 (roughly two fold difference) so it seems unsafe to conclude that only EMC2 has specific interactions with the substrate. In fact we later find that EMC9/EMC8 forms part of the substrate binding cavity. It is stated in the Figure 1---figure supplement 2 legend that the crosslinks between the TA substrate and EMC2 alone are physiologically relevant but those between the substrate and EMC8 and EMC9 are due to co-aggregation with the substrate. How do the authors know this?

We deleted the line suggesting EMC2 is the major contributor to substrate interaction. The primary basis on which we judged whether the crosslinks are functionally relevant (versus non-specific, potentially due to co-aggregation) was whether the substrate-substrate interaction was simultaneously diminished. This is now clarified in the legend.

> 4\) Figure 3. The HLY substitution that perturbs model substrate integration includes the substitution of an amino acid Y191 that has previously been used as a negative control for the BPA crosslinking experiments because it faces away from the binding cavity. It\'s therefore very difficult to infer that substitution of this residue is affecting substrate binding by changing the polarity of the cavity (rather than changing the protein fold).

We have added a caveat (subsection "Functional analysis of the vestibule in the EMC2•EMC9 complex") noting that in addition to hydrophobicity, the mutations might alter the local conformation to account for the phenotype. Of course, the overall fold is not likely to be perturbed given this mutant protein effectively assembles with the rest of EMC.

> 5\) Figure 1---figure supplement 2. The CaM-substrate adduct should be labelled to assist the reader.

This label has been added.

> 6\) Figure 5B. The rotation between the two views appears to be the opposite direction to that indicated in the figure. I appreciate that this figure is included primarily to show the quality of the model fit to the EM density, but I did struggle to assign the subunits by their colours under the EM density overlay. For example I could not identify EMC1. It might be worth labelling the subunits nearest the viewer on the figure.

We apologise this figure was not clearer. The rotation is correct and can be seen by the position of the crossbar moving from the plane of the page to a perpendicular position on the left side. To further clarify this, we have labelled the front-facing subunits as recommended.

> 7\) Figure 5C. It would be helpful to know where the crosslinking substituted amino acids are on the structure in Figure 5D. Similarly, it would be useful to have the identify (aa number) of all the crosslinking amino acids shown in Figure 5D marked on the figure.

We tried extensively to incorporate amino acid labels but it was not possible without making the figure extremely complicated or having the labels be very small. Instead, we have prepared a supplementary figure (Figure 5---figure supplement 3) that shows the primary data for the crosslinking, and in panel F lists the amino acid numbers of the key crosslinking sites depicted on the structural model.

> 8\) Figure 5D. Where is the raw data for this figure for those substitutions not shown in Figure 5C? I do think it is misleading to draw a crosslinking line from the substituted amino acid to an exact position on the crosslinked partner subunit because the position of the acceptor amino acid has not been confirmed experimentally. Minimally the legend should say that the crosslink is drawn to the closest point in the model (rather than saying \`verified crosslinks\'), but perhaps on the figure these could be shown as arrows not quite reaching the partner subunit.

We tried arrows but it was hard to find a clear view where all the arrowheads would be simultaneously visible. We therefore edited the legend as suggested. The primary data documenting the crosslinking are now shown in Figure 5---figure supplement 3.

> 9\) Figure 1---figure supplement 3. The authors should indicate in the legend that both of the proteins analysed are EMC substrates.

Good point. This has been added.

> 10\) Figure 4. The placeholder density referred to in the subsection "Position of the EMC2•EMC9 subcomplex within native EMC" should be indicated on the figure if it is present. If it is not this should be made clear when referring to it in the text. The text should also refer forward to where this density is discussed in detail (or even better all this discussion should be moved to where the structure of the density is analysed in Figure 5).

This is now indicated in the figure and the text edited accordingly. In line with the overall suggestion to be more cautious, we refer to this as a 'potential placeholder' to indicate that our assignment to EMC6 is provisional.

> 11\) Figure 5E. Again I appreciate that this panel is to show the fit of the model to the EM density but I would like to be able to see the model more clearly. I recommend that the authors include another panel/figure showing the model of the lumenal domain in different views.

We agree that it is difficult to see the model through the density. Therefore, a supplementary figure has been added that shows views of the complete EMC model without density (Figure 5---figure supplement 5).

> 12\) Figure 5---figure supplement 3. The TM part of EMC3 should be marked because it is not obvious which helices the modelled EMC3 cytoplasmic density should be associated with. Is there support for the fold of the EMC3 three-helix bundle from a co-evolution model? The raw crosslinking data should be shown.

The three-helix bundle is predicted by co-evolution and this is now noted in the text (subsection "Architecture of the membrane-embedded and lumenal regions of EMC"). The crosslinking data is now provided as part of Figure 5---figure supplement 3. Dashed lines are now drawn between the cytosolic and membrane regions of EMC3.

> 13\) Are there significant parts of the EMC polypeptides that are not included in the model that has been fitted to the EM density?

The main parts that are not accounted in the model are the TM domain of EMC10, and the presumably flexible loops and termini of most subunits. This is now noted at the end of the subsection "Architecture of the membrane-embedded and lumenal regions of EMC".

[^1]: These authors contributed equally to this work.
